Iaso Therapeutics

Funding and NIH signals

• SEC Form D raise Raised $570K (Form D filed Jan 14, 2026). SEC Form D 0000905729-26-000020 (Jan 14, 2026)
  Evidence (1 event)

  • Jan 14, 2026 · SEC Form D 0000905729-26-000020
    Name of Issuer: Iaso Therapeutics, Inc.; CIK: 1961165; Address: East Lansing, MI; Submission type: D; Filing date: 2026-01-14; Industry Group: Biotechnology; Date of First Sale: 2026-01-09; Types of Securities Offered: Option/warrant; Business combination transaction: false; Total Offering Amount: 1800000; Total Amount Sold: 570000; Federal exemptions: 06b
• NIH award NIH awarded $300K (SBIR Phase I 1R43AI197624-01, new, notice Jul 1, 2026). NIH RePORTER 1R43AI197624-01 (Jul 1, 2026)
  Evidence (1 event)

  • Jul 1, 2026 · NIH RePORTER 1R43AI197624-01
    Organization: IASO THERAPEUTICS, INC.; City/State: EAST LANSING, MI; Project number: 1R43AI197624-01; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-07-01; FY total cost (award amount): 299999; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Next generation multi-antigen Staphylococcus aureus vaccine enabled by proprietary mutant bacteriophage Qbeta; Organization type: Domestic For-Profits

Job counts as of Oct 18, 2026. All funding and NIH signals